Skip to main content
. 2012 May;166(1):210–220. doi: 10.1111/j.1476-5381.2011.01662.x

Figure 3.

Figure 3

(A) Selectivity of central Gαi1, Gαi2, Gαi3, Gαo and Gαs targeted ODN pre-treatment on Gα-subunit protein levels normalized to GAPDH and expressed as optical density units per mm2 (mean ± SEM) in the BC, hypothalamic PVN and VLM of male Sprague-Dawley rats pre-treated (24 h; i.c.v.) with a SCR, Gαi1, Gαi2, Gαi3, Gαo or Gαs ODN (25 µg in 5 µL each) (n= 6 per group) *P < 0.05, compared with i.c.v. SCR ODN-pre-treated animal group value; one-way repeated measures anova and (B) representative immunoblots illustrating GAPDH, Gαi1, Gαi2, Gαi3, Gαo and Gαs subunit protein levels in the PVN from male Sprague-Dawley rats pre-treated (24 h; i.c.v.) with a Gαi2 or Gαs ODN sequence.